Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer - Scorecard - MDSpire

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer

  • By

  • Yi Chen

  • Xiaofeng Chen

  • Bowen Yue

  • Xinwei Zhong

  • Hao Zhang

  • Xiaohong Chen

  • Xiangguang Chen

  • Zhuozhi Dai

  • Zhiqi Yang

  • June 18, 2026

  • 0 min

Share

Clinical Scorecard: Development and Validation of an mpMRI Nomogram Combining Clinicopathological Variables to Predict HER2 Status in Breast Cancer

At a Glance

CategoryDetail
ConditionBreast Cancer (BC)
Key MechanismsHER2 expression status determines targeted therapy options.
Target PopulationFemale patients with invasive breast cancer.
Care SettingOncology clinics utilizing multiparametric MRI (mpMRI).

Key Highlights

  • Nomogram developed to predict HER2 status using mpMRI and clinicopathological factors.
  • AUCs of 0.762 and 0.738 achieved for differentiating HER2-over/HER2-low from HER2-zero.
  • Significant predictors include CA125, Ki-67, ADC-min, and early-phase ME.
  • HER2-low BC recognized as a distinct therapeutic entity for T-DXd.
  • Study conducted on 313 patients with a training and validation dataset.

Guideline-Based Recommendations

Diagnosis

  • HER2 status assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

Management

  • HER2-positive patients may benefit from trastuzumab and novel ADCs like trastuzumab deruxtecan (T-DXd).

Monitoring & Follow-up

  • Noninvasive methods like mpMRI can evaluate HER2 expression longitudinally.

Risks

  • Tumor heterogeneity may lead to sampling error in traditional HER2 status assessment.

Patient & Prescribing Data

Female patients with pathologically confirmed invasive breast cancer.

HER2-low expression recognized for targeted therapies, including T-DXd.

Clinical Best Practices

  • Utilize mpMRI parameters alongside clinicopathological factors for HER2 status prediction.
  • Consider dynamic changes in HER2 status during treatment.

Related Resources & Content

Original Source(s)

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer

  • by Yi Chen, Xiaofeng Chen, Bowen Yue, Xinwei Zhong, Hao Zhang, Xiaohong Chen, Xiangguang Chen, Zhuozhi Dai, Zhiqi Yang

  • June 18, 2026

Related Content

2026 AACR Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
Malignant transformation of uterine serosal endometriosis to clear cell carcinoma in a postmenopausal patient: a rare case report

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report